Davis Polk advised the sole book-running manager in connection with the $126.5 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “XNCR.”
Based in Monrovia, California, Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Marcus K. Hintze and Angela J. Koo. The tax team included partner Rachel D. Kleinberg and associate Lena X. Qiu. The intellectual property and technology team included counsel Michelle Ontiveros Gross. Counsel Marcie A. Goldstein provided FINRA advice. Associate Brantley Hawkins provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.